欧康医药
(833230)
| 流通市值：2.61亿 | | | 总市值：10.44亿 |
| 流通股本：1890.79万 | | | 总股本：7563.14万 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 24,000,446.44 | 51,521,096.61 | 147,192,713.47 | 118,479,830.62 |
| 应收票据及应收账款 | 68,130,075.97 | 63,663,660.23 | 51,533,372.45 | 36,682,793.84 |
| 其中：应收票据 | - | 400,000 | 251,756 | 275,475.08 |
| 应收账款 | 68,130,075.97 | 63,263,660.23 | 51,281,616.45 | 36,407,318.76 |
| 预付款项 | 10,041,006.97 | 3,426,414.9 | 12,332,667.7 | 9,666,313.2 |
| 其他应收款合计 | 3,140,138.88 | 2,904,403.48 | 2,835,900.6 | 2,712,220.66 |
| 存货 | 74,387,598.57 | 73,931,694.95 | 68,518,780.17 | 66,297,662.39 |
| 其他流动资产 | 4,415,165.13 | 5,343,318.82 | 2,508,176.65 | 1,592,825.04 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 252,728,292.63 | 294,402,629.11 | 284,921,611.04 | 320,567,537.36 |
| 非流动资产: | | | | |
| 固定资产 | 31,616,052.2 | 32,984,623 | 33,204,158.31 | 33,983,040.89 |
| 在建工程 | 140,573,206.76 | 112,683,779.55 | 78,170,321 | 51,234,431.25 |
| 使用权资产 | 234,467.83 | 263,932.45 | 298,358.43 | 332,784.39 |
| 无形资产 | 11,636,631.14 | 11,779,781.5 | 11,922,623.23 | 12,052,893.73 |
| 递延所得税资产 | 936,985.1 | 936,985.1 | 793,277.61 | 793,277.61 |
| 其他非流动资产 | - | 41,398.94 | 10,716,925.3 | 7,288,937.5 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 184,997,343.03 | 158,690,500.54 | 135,105,663.88 | 105,685,365.37 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 437,725,635.66 | 453,093,129.65 | 420,027,274.92 | 426,252,902.73 |
| 流动负债: | | | | |
| 短期借款 | 11,014,703.4 | 21,015,726.03 | 20,024,873.08 | 25,015,136.99 |
| 交易性金融负债 | - | - | - | 83,600 |
| 应付票据及应付账款 | 11,429,255.93 | 30,881,997.83 | 4,236,859.92 | 6,253,346.85 |
| 应付账款 | 11,429,255.93 | 30,881,997.83 | 4,236,859.92 | 6,253,346.85 |
| 合同负债 | 1,314,206.48 | 541,740.35 | 1,162,024.2 | 4,053,184.39 |
| 应付职工薪酬 | 2,724,600.05 | 2,394,197.71 | 1,376,509.28 | 1,363,270.72 |
| 应交税费 | 1,685,249.44 | 166,200.41 | 298,125.05 | 63,759.51 |
| 其他应付款合计 | 439,524.12 | 624,036.16 | 1,778,971.71 | 535,344.68 |
| 一年内到期的非流动负债 | 143,359.08 | 149,888.93 | - | - |
| 其他流动负债 | - | 70,426.25 | - | 526,913.97 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 28,750,898.5 | 55,844,213.67 | 28,877,363.24 | 37,894,557.11 |
| 非流动负债: | | | | |
| 租赁负债 | - | - | 284,115.91 | 280,125.73 |
| 递延收益 | 5,295,690.22 | 3,874,085.13 | 2,450,463.58 | 2,528,858.5 |
| 其他非流动负债 | 166,371.57 | - | - | - |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 5,462,061.79 | 3,874,085.13 | 2,734,579.49 | 2,808,984.23 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 34,212,960.29 | 59,718,298.8 | 31,611,942.73 | 40,703,541.34 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 75,631,404 | 75,631,404 | 75,631,404 | 75,631,404 |
| 资本公积 | 205,945,776.39 | 205,854,776.4 | 205,595,627.84 | 205,504,627.85 |
| 其他综合收益 | - | -19,067.58 | - | - |
| 专项储备 | 1,655,083.68 | 904,552.09 | - | - |
| 盈余公积 | 16,194,401.47 | 16,194,401.47 | 14,394,901.34 | 14,394,901.34 |
| 未分配利润 | 103,298,286.15 | 94,643,346.54 | 92,432,614.01 | 90,018,428.2 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 402,724,951.69 | 393,209,412.92 | 388,054,547.19 | 385,549,361.39 |
| 少数股东权益 | 787,723.68 | 165,417.93 | 360,785 | - |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 403,512,675.37 | 393,374,830.85 | 388,415,332.19 | 385,549,361.39 |
| 负债和股东权益合计 | 437,725,635.66 | 453,093,129.65 | 420,027,274.92 | 426,252,902.73 |
| 公告日期 | 2024-04-26 | 2024-04-17 | 2023-10-30 | 2023-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |